Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06751992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

Study acronym: Neuro-KTR
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 1, 2025 to Mar 17, 2026 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Dec 1, 2025 to Mar 17, 2026
    • Site details revised
  3. Start date: May 1, 2025 to Dec 1, 2025v3
  4. Study Identification, Study Statusv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
Trial Details
NCT Number NCT06751992
Lead Sponsor Massachusetts General Hospital
Collaborators: Veloxis Pharmaceuticals
Conditions Kidney Transplant Recipients, Old Age
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov